$0.00
(Market cap
$27 Mln
Recently Viewed
Clear AllMarket cap
$27 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
4.9
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-2.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.3
Debt to Equity
5.2
Book Value
$0.3
EPS
$-2.8
Face value
--
Shares outstanding
31,144,497
CFO
$-164.48 Mln
EBITDA
$-209.47 Mln
Net Profit
$-235.21 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Senti Biosciences Inc (SNTI)
| -16.9 | -11.2 | -22.2 | -72.4 | -56.9 | -- | -- |
|
BSE Sensex*
| -9.2 | 1.1 | -8.4 | 2.2 | 8.4 | 9.9 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Senti Biosciences Inc (SNTI)
| -70.4 | -46.5 | -53.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Senti Biosciences Inc (SNTI)
|
0.9 | 27.2 | 0.0 | -61.4 | -285,636.4 | -393.4 | -- | 4.9 |
| 65.1 | 9,121.7 | 1,091.0 | 202.3 | 31.6 | 31.3 | 40.7 | 16.0 | |
| 65.0 | 8,006.8 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.3 | 11,869.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.9 | 5.3 | |
| 78.6 | 10,310.0 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 259.0 | 7,623.9 | 389.1 | 204.8 | 41.5 | 18.9 | 37.9 | 6.3 | |
| 519.6 | 11,919.8 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.8 | |
| 493.5 | 14,094.3 | 2,530.2 | 451.1 | 21.3 | 70.2 | 32.3 | 30.7 | |
| 102.7 | 8,077.1 | 0.0 | -425.4 | -- | -36.7 | -- | 6.5 | |
| 316.1 | 8,804.8 | 0.0 | -303.3 | -- | -45.8 | -- | 10.0 |
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf... healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company's product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma. In addition, it develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to gene therapies for tissue-directed targets, as well as partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Read more
Co-founder, CEO, President & Director
Dr. Timothy K. Lu M.D., Ph.D.
Co-founder, CEO, President & Director
Dr. Timothy K. Lu M.D., Ph.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Senti Biosciences Inc (SNTI) is $0.86 (NASDAQ) as of 10-Apr-2026 13:31 EDT. Senti Biosciences Inc (SNTI) has given a return of -56.91% in the last 3 years.
Since, TTM earnings of Senti Biosciences Inc (SNTI) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.37
|
4.09
|
|
2024
|
-0.33
|
0.68
|
|
2023
|
-0.04
|
0.04
|
|
2022
|
-0.09
|
0.03
|
|
2021
|
--
|
--
|
The 52-week high and low of Senti Biosciences Inc (SNTI) are Rs 5.10 and Rs 0.77 as of 13-Apr-2026.
Senti Biosciences Inc (SNTI) has a market capitalisation of $ 27 Mln as on 10-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Senti Biosciences Inc (SNTI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.